Glaukos Corporation (GKOS)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$2.31 (+1.70%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Glaukos Corporation (GKOS)
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Key Insights

Critical company metrics and information

  • Share Price

    $138.27

  • Market Cap

    $7.62 Billion

  • Total Outstanding Shares

    55.14 Million Shares

  • Total Employees

    907

  • Dividend

    No dividend

  • IPO Date

    June 25, 2015

  • SIC Description

    Surgical & Medical Instruments & Apparatus

  • Homepage

    https://www.glaukos.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$23.12 Million
Net Cash Flow From Investing Activities, Continuing$23.12 Million
Net Cash Flow From Financing Activities$38.73 Million
Net Cash Flow$-10.64 Million
Net Cash Flow From Financing Activities, Continuing$38.73 Million
Net Cash Flow From Operating Activities$-72.49 Million
Net Cash Flow From Operating Activities, Continuing$-72.49 Million
Net Cash Flow, Continuing$-10.64 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Average Shares$105.36 Million
Net Income/Loss Attributable To Parent$-149.57 Million
Benefits Costs and Expenses$508.97 Million
Diluted Earnings Per Share$2.93
Preferred Stock Dividends And Other Adjustments$0.00
Basic Earnings Per Share$2.93
Net Income/Loss$-149.57 Million
Selling, General, and Administrative Expenses$255.20 Million
Diluted Average Shares$105.36 Million
Income/Loss From Continuing Operations After Tax$-149.57 Million
Cost Of Revenue$84.28 Million
Operating Expenses$408.39 Million
Income/Loss From Continuing Operations Before Tax$-148.63 Million
Nonoperating Income/Loss$-16.30 Million
Income Tax Expense/Benefit$946000.00
Other Operating Expenses$153.19 Million
Gross Profit$276.06 Million
Revenues$360.35 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Available To Common Stockholders, Basic$-149.57 Million
Operating Income/Loss$-132.32 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Costs And Expenses$508.97 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$186.35 Million
Other Non-current Assets$161.26 Million
Other Current Assets$337.39 Million
Liabilities$258.03 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$668.51 Million
Noncurrent Assets$529.26 Million
Intangible Assets$269.42 Million
Equity$668.51 Million
Current Assets$397.28 Million
Fixed Assets$98.58 Million
Assets$926.54 Million
Other Current Liabilities$60.58 Million
Liabilities And Equity$926.54 Million
Current Liabilities$71.68 Million
Inventory$59.90 Million
Accounts Payable$11.10 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.